<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399994</url>
  </required_header>
  <id_info>
    <org_study_id>ABILITY</org_study_id>
    <nct_id>NCT03399994</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES</brief_title>
  <official_title>A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES for Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: an Investigator-initiated Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mediolanum Cardio Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare angiographic and clinical performance of Abluminus
      DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical investigation is designed as a prospective, multicentre, national,
      randomized, open label, 2-arm parallel group, pilot trial comparing Abluminus DES+ versus
      Everolimus-eluting DES on Late Lumen Loss and clinical outcomes in diabetic patients
      undergoing Percutaneous Coronary Intervention.

      A total of 165 patients will be recruited and randomized in the two groups in a 2:1 ratio at
      up to 6-8 Italian sites.

      After index procedure, patients will be followed up by angiographic follow-up at 9 months and
      clinical follow-up at 12 months.

      The study design is open label, since it is not possible to blind the investigators as to the
      stent type. However the members of the Event Adjudication Committee will be blinded to the
      patient. assignment. All medical records, source documentation and event information
      collected for the adjudication process will be blinded to treatment assignment.

      In addition the primary endpoint will be independently evaluated by the Core-Lab which will
      be blinded as to group assignment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized multi-centre controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The members of the Event Adjudication Committee will be blinded to the patient assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent neointimal volume</measure>
    <time_frame>9-month follow-up</time_frame>
    <description>In-stent neointimal volume, measured with OCT, following PCI with Abluminus DES+ compared with in-stent neointimal volume following PCI with Everolimus-eluting DES.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neointimal area</measure>
    <time_frame>9-month follow-up</time_frame>
    <description>Neointimal area, calculated at the site of minimal lumen area measured with OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>12 months</time_frame>
    <description>This will be a composite of cardiac death, target-vessel MI, and clinically indicated TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>This is defined according to classification proposed by the Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
    <description>Any death due to proximate cardiac cause (eg, MI, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel myocardial infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Any MI that, irrespective of the time after the index procedure, is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause33 Type of acute MI is classified according to the Joint ESC/ACCF/AHA/ WHF Joint Task Force for the Universal Definition of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>repeat revascularization will be defined as any repeat PCI or new coronary artery bypass graft (CABG) surgery within the first year post-PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>deployment of the assigned stents without system failure or device-related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>24 hours</time_frame>
    <description>Attainment of &lt;50% residual stenosis of the target lesion using post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>24 hours</time_frame>
    <description>Lesion success without the occurrence of Major Adverse Cardiac Events during the hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>ABLUMINUS DES+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>device implantation during coronary angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>device implantation during coronary angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>device implantation during coronary angioplasty</intervention_name>
    <description>device implantation during coronary angioplasty</description>
    <arm_group_label>ABLUMINUS DES+</arm_group_label>
    <arm_group_label>Everolimus-eluting DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;18

          2. Diabetes mellitus

          3. Documented CAD: stable or unstable angina, Non-ST segment MI, silent ischemia or
             positive functional study

          4. PCI considered appropriate and feasible

          5. Culprit de novo lesion in a native coronary artery with significant stenosis (&gt;50% by
             visual estimate) eligible for stent implantation (no limitation on the number of
             treated lesions, vessel and lesion length);

          6. Patient provides written informed consent

          7. Patient agrees to all required follow-up procedures and visits.

          8. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm.

        Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to any of the following
             medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus, everolimus, and/or
             contrast media (patients with documented sensitivity to contrast which can be
             effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be
             enrolled. Patients with true anaphylaxis to prior contrast media, however, should not
             be enrolled);

          2. Any contraindication to the implant of the Abluminus DES+

          3. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not
             surgically sterile, 2 years postmenopausal, or does not consistently use effective
             methods of contraception;;

          4. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions;

          5. Previous coronary intervention on target vessel in the 3-months prior to enrollment;

          6. Non-cardiac co-morbid conditions with life expectancy &lt;1 year or that may result in
             protocol non-compliance (per site investigator's medical judgment);

          7. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period;

          8. Previously documented left ventricular ejection fraction (LVEF) &lt;30%;

          9. Evident cardiogenic shock before randomization;

         10. Patients with left main stem stenosis (&gt;50% by visual estimate);

         11. In-stent restenosis;

         12. ST-segment elevation MI;

         13. Chronic total occlusion.

         14. Culprit lesion to a Saphenous Vein graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Colombo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azeem Latib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Moffa, BSc</last_name>
    <phone>026125141</phone>
    <email>moffa@mcr-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Cristina Jori, MD</last_name>
    <phone>026125141</phone>
    <email>jori@mcr-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Bolognini</name>
      <address>
        <city>Seriate</city>
        <state>Bergamo</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Tespili, MD</last_name>
      <phone>0353063319</phone>
      <email>tespili@katamail.com</email>
    </contact>
    <investigator>
      <last_name>Maurizio Tespili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Miano</city>
        <state>Milano</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azeem Latib, MD</last_name>
      <phone>0226437331</phone>
      <email>alatib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernhard Reimers, MD</last_name>
      <phone>0282247384</phone>
      <email>bernhard.reimers@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Bernhard Reimers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Testa, MD</last_name>
      <phone>0252774987</phone>
      <email>luctes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luca Testa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Anna</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bindo Missiroli, MD</last_name>
      <phone>09615070254</phone>
      <email>bindo.missiroli@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Bindo Missiroli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Ferrario, MD</last_name>
      <phone>0382501598</phone>
      <email>m.ferrario@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Ferrario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Pietro, Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Monti, MD</last_name>
      <phone>0633582119</phone>
      <email>montifrancesco@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Monti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Muraglia, MD</last_name>
      <phone>0461903892</phone>
      <email>simone.muraglia@apss.tn.it</email>
    </contact>
    <investigator>
      <last_name>Simone Muraglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

